Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

APC debuts ‘medicine accelerator’ in collaboration with Enterprise Ireland

By Brian Buntz | July 7, 2021

APC pharmaThe Dublin-based pharmaceutical R&D firm APC Ltd has launched a ‘Global Centre of Excellence for Vaccine and Advanced Therapeutic Research and Manufacturing.’

The result of a €25 million investment, the new facility will staff 120 new employees.

The facility will have the capacity to produce hundreds of millions of doses of vaccines (including for COVID-19) and other therapeutic products annually.

The new plant will link to supply chains in the U.S. and Europe. Approximately half of APC’s customers are based in the U.S. APC also owns an office in Boston. The trial involves some 400 patients. The protein-based vaccine uses a synthetic version of the SARS-CoV-2 spike protein.

APC is currently partnering with the Australian company Vaxine (Adelaide), which has a Phase 2 trial underway in Iran for a COVID-19 vaccine. Vaxine is a spin-off of Australia’s National Health Sciences Center.

APC facility

APC, an Irish pharmaceutical R&D company, debuts €25m investment and 120 jobs to accelerate development and manufacture of COVID-19 vaccines and other therapeutics. Shown here is Becca Dunne, process development engineer III.

APC’s ‘Global Centre of Excellence for Advanced Therapeutic and Vaccine Research and Manufacture’ will also draw support from Enterprise Ireland, the Irish government agency charged with driving the growth of Irish enterprises in global markets. In particular, Enterprise Ireland will support accelerated process development of vaccine candidates and other drug development at the new research facility. Enterprise Ireland will also offer strategic funding for VLE Therapeutics, a sister company of APC, to support the manufacturing of therapeutics and vaccines.

Some €8 million of APC’s total €25 million investment will cover the construction of an additional 12,000 sq ft laboratory and a 60,000 sq ft headquarters. The company expects the facilities to be operational by the end of June 2021.

The remaining $17 million will go to VLE Therapeutics to manufacture vaccines and advanced therapeutics, including cell and gene therapies.

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: APC, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, vaccine manufacturing
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50